BACKGROUND: Diets containing omega-3 (ω-3) fat have been associated with decreased tumor development in the colon, breast, and prostate. We assessed the effects of a diet rich in ω-3 fat on the development of pancreatic precancer in elastase (EL)-Kras transgenic mice and examined the effect of an ω-3 fatty acid on pancreatic cancer cells in vitro. MATERIALS AND METHODS: Two cohorts of EL-Kras mice were fed a high ω-3 fat diet (23% menhaden oil) for 8 and 11 mo and compared with age-matched EL-Kras mice fed standard chow (5% fat). Pancreata from all mice were scored for incidence and frequency of precancerous lesions. Immunohistochemistry was performed for proliferating cell nuclear antigen (PCNA) to assess proliferative index in lesions of mice fed either a high ω-3 or standard diet. In vitro, the effect of the ω-3 fatty acid, docosahexaenoic acid (DHA), on two pancreatic cancer cell lines was assessed. Cancer cell proliferation was assessed with an MTT assay; cell cycle analysis was performed by flow cytometry; and apoptosis was assessed with annexin/PI staining. RESULTS: The incidence, frequency, and proliferative index of pancreatic precancer in EL-Kras mice was reduced in mice fed a high ω-3 fat diet compared with mice fed a standard chow. In vitro, DHA treatment resulted in a concentration-dependent decrease in proliferation through both G1/G0 cell cycle arrest and induction of apoptosis. CONCLUSIONS: A high ω-3 fat diet mitigates pancreatic precancer by inhibition of cellular proliferation through induction of cell cycle arrest and apoptosis.
BACKGROUND: Diets containing omega-3 (ω-3) fat have been associated with decreased tumor development in the colon, breast, and prostate. We assessed the effects of a diet rich in ω-3 fat on the development of pancreatic precancer in elastase (EL)-Krastransgenic mice and examined the effect of an ω-3 fatty acid on pancreatic cancer cells in vitro. MATERIALS AND METHODS: Two cohorts of EL-Krasmice were fed a high ω-3 fat diet (23% menhaden oil) for 8 and 11 mo and compared with age-matched EL-Krasmice fed standard chow (5% fat). Pancreata from all mice were scored for incidence and frequency of precancerous lesions. Immunohistochemistry was performed for proliferating cell nuclear antigen (PCNA) to assess proliferative index in lesions of mice fed either a high ω-3 or standard diet. In vitro, the effect of the ω-3 fatty acid, docosahexaenoic acid (DHA), on two pancreatic cancer cell lines was assessed. Cancer cell proliferation was assessed with an MTT assay; cell cycle analysis was performed by flow cytometry; and apoptosis was assessed with annexin/PI staining. RESULTS: The incidence, frequency, and proliferative index of pancreatic precancer in EL-Krasmice was reduced in mice fed a high ω-3 fat diet compared with mice fed a standard chow. In vitro, DHA treatment resulted in a concentration-dependent decrease in proliferation through both G1/G0 cell cycle arrest and induction of apoptosis. CONCLUSIONS: A high ω-3 fat diet mitigates pancreatic precancer by inhibition of cellular proliferation through induction of cell cycle arrest and apoptosis.
Authors: Mirjam Luijten; Aart Verhoef; Jan A M A Dormans; Rudolf B Beems; Hans W J M Cremers; Nico J D Nagelkerke; Herman Adlercreutz; José L Peñalvo; Aldert H Piersma Journal: Reprod Toxicol Date: 2006-12-10 Impact factor: 3.143
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Kimberly S Andrews; Durado Brooks; John Bond; Chiranjeev Dash; Francis M Giardiello; Seth Glick; David Johnson; C Daniel Johnson; Theodore R Levin; Perry J Pickhardt; Douglas K Rex; Robert A Smith; Alan Thorson; Sidney J Winawer Journal: Gastroenterology Date: 2008-02-08 Impact factor: 22.682
Authors: Justin Hering; Sean Garrean; Thomas R Dekoj; Anthony Razzak; Abdul Saied; Jose Trevino; Tricia A Babcock; N Joseph Espat Journal: Ann Surg Oncol Date: 2007-09-26 Impact factor: 5.344
Authors: David S Lamb; David Slaney; Robin Smart; John N Nacey; Grant Russell; Belinda Scott; Carol A Johnson; John D Adams; Sandra Moran; Brett Delahunt Journal: Pathology Date: 2007-12 Impact factor: 5.306
Authors: Malisetty V Swamy; Bhargava Citineni; Jagan M R Patlolla; Altaf Mohammed; Yuting Zhang; Chinthalapally V Rao Journal: Nutr Cancer Date: 2008 Impact factor: 2.900
Authors: Eric C Cheon; Matthew J Strouch; Morgan R Barron; Yongzeng Ding; Laleh G Melstrom; Seth B Krantz; Bhargava Mullapudi; Kevin Adrian; Sambasiva Rao; Thomas E Adrian; David J Bentrem; Paul J Grippo Journal: Int J Cancer Date: 2010-10-26 Impact factor: 7.396
Authors: Jami L Saloman; Kathryn M Albers; Zobeida Cruz-Monserrate; Brian M Davis; Mouad Edderkaoui; Guido Eibl; Ariel Y Epouhe; Jeremy Y Gedeon; Fred S Gorelick; Paul J Grippo; Guy E Groblewski; Sohail Z Husain; Keane K Y Lai; Stephen J Pandol; Aliye Uc; Li Wen; David C Whitcomb Journal: Pancreas Date: 2019-07 Impact factor: 3.327
Authors: Sandeep Nadella; Julian Burks; Abdulhameed Al-Sabban; Gloria Inyang; Juan Wang; Robin D Tucker; Marie E Zamanis; William Bukowski; Narayan Shivapurkar; Jill P Smith Journal: Am J Physiol Gastrointest Liver Physiol Date: 2018-06-21 Impact factor: 4.052
Authors: Rick J Jansen; Dennis P Robinson; Ryan D Frank; Kristin E Anderson; William R Bamlet; Ann L Oberg; Kari G Rabe; Janet E Olson; Rashmi Sinha; Gloria M Petersen; Rachael Z Stolzenberg-Solomon Journal: Int J Cancer Date: 2013-10-29 Impact factor: 7.396
Authors: Altaf Mohammed; Naveena B Janakiram; Misty Brewer; Ashley Duff; Stan Lightfoot; Richard S Brush; Robert E Anderson; Chinthalapally V Rao Journal: Neoplasia Date: 2012-12 Impact factor: 5.715
Authors: Alfredo Erazo-Oliveras; Natividad R Fuentes; Rachel C Wright; Robert S Chapkin Journal: Cancer Metastasis Rev Date: 2018-09 Impact factor: 9.264